Program
ibuzatrelvir
Also written as “PF-07817883”, “Ibuzatrelvir co-process API film coated tablet” and “Ibuzatrelvir filmcoated tablet”.
In Pfizer's pipeline, SARS-CoV-2 3CL protease inhibitor
. Its studies are mostly in COVID-19, led by Pfizer.
Furthest: phase 3, since Nov 5, 202411 company-led studies, 2 open or runningNext primary completion: Sep 28, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 112 open or running | phase 3since Nov 5, 2024 | Oct 11, 2022 | Sep 28, 2027phase 3 · NCT07013474 |
- Named in Pfizer’s own pipeline as
ibuzatrelvir PF-07817883
, phase 3, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 11, 2022First study: phase 1 study in COVID-19First studyNCT05580003 · 94 enrolled · United States, Belgium
- Apr 4, 2023Phase 2 study in COVID-19NCT05799495 · 240 enrolled · United States
- Apr 10, 2023Phase 1 study in COVID-19NCT05822440 · 12 enrolled · United States
- May 23, 2023Phase 1 study in COVID-19NCT05884554 · 21 enrolled · United States
- Oct 10, 2023Phase 1 study in HealthyNCT06122194 · 12 enrolled · Belgium
- Aug 1, 2024Phase 1 study in COVID-19NCT06586216 · 16 enrolled · United States
- Oct 15, 2024Phase 1 study in HealthyNCT06646042 · 12 enrolled · United States
- Nov 5, 2024Phase 3 study in Pneumonia, ViralNCT06679140 · 2,330 planned · United States, Argentina, Belgium and more
- May 5, 2025Phase 3 study in COVID-19NCT07013474 · 300 planned · United States, Argentina, Belgium and more
- Nov 14, 2025Phase 1 study in COVID-19NCT07235137 · 12 enrolled · China
- Apr 7, 2026Phase 1 study in COVID-19NCT07552779 · 17 enrolled · Belgium
Ahead
- Sep 28, 2027Primary completion: phase 3 study in COVID-19NCT07013474
- Oct 1, 2027Primary completion: phase 3 study in Pneumonia, ViralNCT06679140
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“SARS-CoV-2 3CL protease inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable, second-generation inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (Mpro; 3C-like protease; 3CL protease; 3CLpro; nsp5 protease), with potential antiviral activity against SARS-CoV-2 and other coronaviruses. Upon oral administrati…”NCIt, read by Claude
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07552779COVID-19 · Belgium | 1 | Completed | Jun 3, 2026 | 17 |
| NCT07235137COVID-19 · China | 1 | Completed | Nov 21, 2025 | 12 |
| NCT07013474COVID-19 · United States, Argentina, Belgium and more | 3 | Recruiting | Sep 28, 2027 | 300 |
| NCT06679140Pneumonia, Viral · United States, Argentina, Belgium and more | 3 | Recruiting | Oct 1, 2027 | 2,330 |
| NCT06646042Healthy · United States | 1 | Completed | Jan 17, 2025 | 12 |
| NCT06586216COVID-19 · United States | 1 | Completed | Feb 13, 2025 | 16 |
| NCT06122194Healthy · Belgium | 1 | Completed | Jan 12, 2024 | 12 |
| NCT05884554COVID-19 · United States | 1 | Completed | Jun 27, 2024 | 21 |
| NCT05822440COVID-19 · United States | 1 | Completed | Jul 10, 2023 | 12 |
| NCT05799495COVID-19 · United States | 2 | Completed | Sep 13, 2023 | 240 |
| NCT05580003COVID-19 · United States, Belgium | 1 | Completed | Sep 15, 2023 | 94 |
How it is read
Names in the registry
- “PF-07817883”, 5 entries
- “ibuzatrelvir”, 3 entries
- “Ibuzatrelvir co-process API film coated tablet”, 1 entry
- “Ibuzatrelvir filmcoated tablet”, 1 entry
- “Ibuzatrelvir”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.